Development, Commercialization and Supply Agreement - Additional Information (Detail)	1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 31, 2016 USD ($)	Feb. 26, 2015 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($) Item	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
License And Collaboration Agreements [Line Items]
Licensing revenue			$ 293,000	$ 296,000	$ 586,000	$ 532,000
Deferred revenue			$ 14,800,000		$ 14,800,000		$ 15,100,000
Eddingpharm
License And Collaboration Agreements [Line Items]
Non-refundable up-front received		$ 15,000,000
Licensing agreement term		16 years
Number of indications of the regulatory milestone events relating to the submission and approval | Item					3
Amounts to be received upon achievement of the regulatory milestone events					$ 33,000,000
Sales-based milestone event payment					120,000,000
Eddingpharm | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone					153,000,000
Amounts to be received upon achievement of the regulatory milestone events					15,000,000
Sales-based milestone event payment					50,000,000
Eddingpharm | Minimum
License And Collaboration Agreements [Line Items]
Amounts to be received upon achievement of the regulatory milestone events					1,000,000
Sales-based milestone event payment					$ 5,000,000
Eddingpharm | Clinical Trial Application
License And Collaboration Agreements [Line Items]
Licensing agreement term	4 years
Non-refundable milestone payment	$ 1,000,000
Biologix FZCo
License And Collaboration Agreements [Line Items]
Revenue recognition period of non-refundable up-front payment	10 years